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The pathogenesis of autoimmune disease can be considered
under two broad headings: firstly, the failure of the mechanisms
by which tolerance to self antigens is maintained, and secondly
the processes on the effector side of the immune system that
lead to tissue damage once tolerance is broken. In this article
we propose to highlight recent developments, with particular
reference to renal autoimmunity, and then to consider some of
the therapeutic implications of our improved understanding of
pathogenesis.
There are three classical mechanisms of tolerance: 1) the
deletion or inactivation of autoreactive clones of lymphocytes;
2) the active suppression of such autoreactive cells; and 3) the
sequestration or masking of autoantigens so that they are not
"visible" to the immune system. Recent experiments have
confirmed the existence and advanced our understanding of a T
cell clonal deletion/inactivation mechanism [1—3], whereas evi-
dence for suppressor systems in the maintenance of tolerance
is, as yet, lacking [4, 5]. However, as considered below, it is too
soon to conclude that suppression has no part to play in self
tolerance.
A substantial body of work indicates a crucial role for T cells
in the maintenance of self tolerance. While it seems clear that
some degree of tolerance is imposed on B cells [61, self-reactive
B cells can readily be demonstrated in normal individuals [7]
and may indeed be vital for the correct development of the
immune system [81. Although tolerance at the B cell level may
have some part to play, to understand tolerance it is necessary
to consider the manner in which T cells interact with self (and
foreign) antigens. A major difference between the B cell and its
receptor (antibody) on the one hand and the T cell and its
receptor on the other, is that the former can interact with free
antigen, whereas the latter can only interact with antigen on cell
surfaces, bound to products of the major histocompatibility
complex (MHC). Understanding of this binding between anti-
gen and MHC products has lately advanced rapidly. It is now
clear that the immune response (Ir) gene phenomenon, in which
it can be demonstrated that possession of a particular MHC
gene allows an immune response to a particular antigen, is due
largely to the specific molecular interactions between the two
[9]. The features of an antigen that enable this association to
occur are emerging, both for interaction with MHC molecules
in general [10, II] and for specific MHC molecules [12]. The
combination of antigen and MHC molecule is then recognized
by the T cell receptor. These three elements—antigen, MHC
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encoded molecule, and T cell receptor—confer the essential
specificity on the immune (or autoimmune) response. Since
tolerance requires the specific inactivation of T cells, it seems
likely on first principles that it would also be restricted by MHC
molecules, and there is indeed experimental support for this
[13, 14]. What is known about these three critical elements will
be discussed with reference to renal autoimmunity.
Autoantigens
Current knowledge about a number of autoantigens important
in renal autoimmune disease is summarized in Table 1. All these
autoantigens are defined (or are being defined) by reactivity
with autoantibodies. They therefore represent the epitopes (that
is, the portion of an antigen reacting with antibody or T cell
receptor) recognized by B cells, not T cells, which as indicated
above are probably of more fundamental importance. The
epitopes recognized by B and T cells are likely to be sited on the
same molecule, but need not be, as inter-molecular intra-
structural linkage (that is, T cell recognizing one cell component
helping the B cell response to a separate component of the same
cell) is well documented [21].
Progress in defining the targets of autoantibodies can be
expected to continue, particularly with the addition of tech-
niques such as the screening of expression eDNA libraries,
which has lately been used to identify the targets of autoanti-
bodies in other autoimmune diseases such as primary biliary
cirrhosis [22].
MHC
Two general considerations follow from the strong MHC
linkage of most autoimmune diseases (examples in nephrology
are the association of DR2 with antiglomerular basement mem-
brane (GBM) disease [23] and of DR3 with membranous
nephropathy [24]). Firstly, as it is the T cell that recognizes
antigen in the context of the MHC, and not the B cell, this
linkage is yet further evidence for the key role of T cells in the
pathogenesis of these diseases. Secondly, the MHC association
suggests that tolerance to self is only broken to a very limited
number of epitopes, possibly only one. The reason for this
deduction is the converse of the explanation for the rarity of Ir
gene effects in the immune response to pathogens in man.
Because such complex structures as viruses and bacteria posses
a multitude of different epitopes, it is most unlikely that an
individual will be unable to bind some of these with their MHC
molecules. It is therefore very rare to be unable to respond, and
it is correspondingly difficult to identify which MHC molecules
are involved in the response to such complex antigens. The fact
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that by contrast MHC associations are readily identifiable in
many autoimmune diseases indicates the much simpler struc-
ture of the corresponding autoantigen, as seen by the autoreac-
tive T cell.
Since this aspect (MHC linkage) is central to understanding
autoimmunity, it is worth considering how this area has ad-
vanced. The analysis of individual MHC disease associations
has progressed by a number of steps of increasing sophistica-
tion. The first is the serological definition of MHC products,
which still provides the bulk of the information. However, a
single serological specificity can cover a number of different,
albeit related, MHC gene products. More precision is achieved
by the use of restriction fragment length polymorphisms
(RFLP). This exploits the fact that different alleles at an MHC
locus, which may produce products with the same serological
specificity, can differ in their possession of target sites for
restriction enzymes. When DNA is cut by such enzymes and
the fragments labelled with probes for the desired locus, the
different alleles produce fragments of different sizes which may
be identified in a suitable gel separation system. This approach
has been used, for example, to identify a particular allele of
DQw3 that is strongly associated with rheumatoid arthritis [25].
To our knowledge, this technique has only been applied in the
field of renal autoimmunity to membranous nephropathy [26]
and failed to produce any evidence for a disease specific allele
within the DR3 specificity. However, the existence of such an
allele can only be confirmed or excluded by use of the most
sophisticated technique, namely the direct sequencing of the
DNA of the alleles involved. The feasibility of this has im-
proved dramatically with the development of rapid methods of
sequencing [27]. These have not yet been applied to renal
autoimmune disease, but have been informative in other cases.
Thus there is evidence for a positive association between a
disease specific allele at the DQJ3 locus and the autoimmune
skin disease pemphigus vulgaris [281. The negative association
(that is, presence of an allele linked with protection from
disease) between other such DQp alleles and insulin-dependent
diabetes mellitus (IDDM) [29] is considered in the section on
suppression.
The concordance rate in studies of identical twins with IDDM
is approximately 50% [30], indicating that environmental influ-
ences are important. In addition other genetic factors such as
Gm allotypes are also involved, and it is therefore unreasonable
to suppose that the type of MHC analysis outlined above will be
revealing in every case. Conversely, it would be surprising if
the application of RFLP analysis and direct sequencing of MHC
genes does not advance understanding of autoimmunity and
renal disease.
T cell
Little is known about autoreactive T cells in man as the
technical problems involved in their isolation and growth are
formidable. The difficulties are closely related to the problems
in identifying autoantigens seen by T cells, as the availability of
one would facilitate the isolation and study of the other.
However, such T cells have been defined in myasthenia gravis
[311 and autoimmune thyroid disease [32], and the next few
years should see progress in this area. This will reflect the
availability of new techniques, for example the growth of
autoreactive T cells in the absence of antigen [33] and the use of
such T cells to screen cDNA expression libraries for T cell
epitopes [34].
The same techniques that are used for the analysis of the
MHC and autoimmunity can in principle be applied to the
autoreactive T cell receptor. There is as yet no information on
serologically-defined T cell receptor alleles in autoimmunity.
These would be analogous to the well defined Gm allotypes on
immunoglobulin molecules, such as those associated with anti-
GBM disease [35]. However, RFLP analysis has demonstrated
that a particular T cell receptor beta chain constant region
polymorphism is associated with membranous nephropathy
[36]. Direct sequencing of the T cell receptor gene will require
cloned autoreactive T cells, which are not as yet available in the
renal autoimmune diseases.
Active suppression of autoreactivity
Little is known about the putative immunoregulatory disor-
ders underlying human renal autoimmunity, but it is an area of
great importance—its understanding offers the best chance of
developing specific immunotherapies.
Experimental work has identified two major systems in-
volved in immunoregulation: the idiotypic network and the
suppressor cell system. Although usually associated with the
humoral and cellular components of the immune system, re-
spectively, there is probably a close connection between the
two mechanisms. Thus perturbation of the normal development
of B cells profoundly affects the T suppressor cell repertoire
[37], and, of relevance to renal autoimmunity, in an experimen-
tal model of interstitial nephritis a dominant idiotype is shared
between anti-tubular basement membrane (TBM) antibodies
and suppressor cells [38].
Idiotypic regulation
Although established in a number of experimental systems
[reviewed in 39], evidence for this mechanism in autoimmune
disease in man is sparse. The only convincing case in which
anti-idiotypic antibodies have been shown to be involved in the
regulation of autoimmunity is the control of anti-factor VIII:c
autoantibodies [40]. However, other specific attempts to dem-
onstrate anti-idiotypic antibodies in both renal [41] and non-
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renal autoimmunity [42] have failed, despite earlier claims in the
latter case [43, 44]. However, the very restricted B cell re-
sponse seen in a number of renal diseases (Table 1) hints at
some form of control via the idiotypic network; once tolerance
is broken at the T cell level there is in principle no reason why
the autoreactive T cell should not help a range of B cells specific
for other linked epitopes. That this does not happen in many
autoimmune diseases could have explanations other than idio-
typic control, such as tolerance imposed at the B cell level [6].
It is a difficult but important experimental challenge to deter-
mine the relative importance of the mechanisms responsible for
this restricted response, which, whatever its cause, has thera-
peutic implications.
Suppression
There are many published studies on defects of non-specific
suppression in human autoimmune disease [45]. By contrast,
the only two well documented examples of antigen-specific
defects that we are aware of involve autoimmune thyroid [46]
and liver disease [47]. However, the association between par-
ticular DQ alleles, namely those possessing an aspartate residue
at position 57 of the f3 chain, and resistance to IDDM [29]
mentioned previously may be relevant here. There are now a
number of examples in which products of the DQ locus are
involved in suppressing the immune response to exogenous
antigens [reviewed in 48], that is, the locus is acting as an
immune suppression (Is) gene locus. An attractive explanation
for this association is that possession of a particular DQ allele,
acting as an Is gene, leads to suppression of the autoimmune
response to the islet cells, and the lack of this gene leads to
susceptibility to autoimmunity. Using this model as a guide, a
re-examination of the MHC associations of autoimmune dis-
eases, searching for similar negative associations, may provide
hints as to which diseases are worth investigating for evidence
of antigen-specific suppression.
There has been progress in dissecting the suppressor cell
systems involved in animal models of interstitial autoimmune
renal disease [49, 50]. An intriguing model is the nephritis found
in kdkd mice, which is inherited in an autosomal recessive
manner [51]. Analysis has revealed the presence of contra-
suppressor cells, which act, as their name implies, by reducing
the action of suppressor cells, thus facilitating the development
of autoimmunity. Analogies, both histological and genetic,
between this animal model and the human medullary cystic
disease/juvenile nephronopthisis complex have suggested that
similar regulatory abnormalities may underlie the human dis-
ease [52].
Sequestration or masking of autoantigens
In its simplest form this long standing concept of tolerance is
based on the notion that certain bodily structures, for anatom-
ical reasons, are not exposed to immuno-competent cells. The
latest variant of this idea involves control of MHC molecule
expression [53]. MHC molecules fall into two classes, class I
and class II. Class I molecules are expressed on essentially all
nucleated cells, and act as restriction elements for cytotoxic T
cells. Their principal role is probably the control of viral
infections, allowing cytotoxic T cells to kill virus-infected host
cells. Class II molecules have a more restricted distribution and
are normally only expressed on components of the immune
system specialized for antigen presentation (such as macro-
phages, dendritic cells, and B cells). These molecules act as
restriction elements for helper and inducer T cells, which play
a key role in the immune response by helping both B cells and
cytotoxic T cells. It was observed that tissues such as thyroid
gland undergoing an autoimmune attack expressed class II
molecules, which the normal tissue does not. This led to the
proposal that such aberrant class II expression allowed T
helper/inducer cells to recognize previously "invisible" autoan-
tigens on the surface of cells. This aberrant expression could be
caused by cytokines such as gamma interferon, released as the
result of a viral infection. The resulting autoreactive T cells
would then initiate the autoimmune process. It now seems
likely that this abnormal expression is not sufficient in itself to
initiate the autoimmune process [54],but may well be important
in its perpetuation. We are not aware of any data on class II
expression in renal autoimmunity, but it would be surprising if
the release of mediators such as gamma interferon during the
autoimmune process did not lead to the upregulation of class II
expression. However, the significance of this is difficult to
interpret, as in a rat model of renal transplantation, rejected and
tolerated grafts had similar increases in class II expression [55].
Effector mechanisms in autoimmunity
There are a vast array of effector mechanisms available to the
immune system, which this paper will not comprehensively
cover. One recent idea is that a group of autoimmune diseases
typified by systemic lupus erythematosus (SLE) is caused
primarily by abnormalities in the effector side of the immune
response, specifically in the handling of immune complexes.
Clearance of immune complexes
Abnormal handling of immune complexes may well be a key
regulatory defect in diseases such as SLE. This hypothesis has
been outlined in greater detail elsewhere [56] and will only be
summarized here. In normal individuals, the bulk of immune
complexes, solubilized by the complement system, are proba-
bly carried via the CR1 receptor on red blood cells to the liver
for proteolytic disposal. In the presence of abnormalities of the
complement system or receptor, either congenital or acquired,
complexes are not cleared as efficiently by this route and can
deposit in target organs such as the kidney. Here they set up an
inflammatory response, which by the release of cytokines and
autoantigens drives the production of autoantibodies. This
leads to the formation of further immune complexes and the
perpetuation of the cycle. In this type of disease, therefore,
there may not be the fundamental breakdown of self tolerance
discussed earlier. Instead there is over production of what may
well be physiological autoantibodies, normally involved in the
safe disposal of effete cells and their breakdown products. It is
a defect on the effector side of the immune system that results
in disease.
This type of mechanism may well be important in the
perpetuation of other autoimmune diseases even if it is not
critically involved in their initiation. For example the polymeric
IgA and IgA rheumatoid factor found in IgA nephropathy can
inhibit the ability of complement to solubilize immune com-
plexes [57]. Although this does not explain the initial abnormal-
ities in IgA, it is easy to see how it may contribute to the
resulting tissue damage.
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Cellular mechanisms
Although the pathogenic role of autoantibodies in renal [58]
and non-renal [59] autoimmune disease has been clear for some
time, it is only relatively recently that the importance of a direct
role for T cells (as opposed to their indirect effect in helping
autoantibody formation) has been accepted. This has been
shown clearly in animal models of renal autoimmunity [50, 60,
61], and there is also indirect evidence in man [62]. These T
cells can cause damage directly via cellular cytotoxic mecha-
nisms, and can also recruit in macrophages which contribute
substantially to the increased glomerular cellularity and cres-
cent formation in acute crescentic nephritis [63]. The macro-
phages and possibly the endogenous glomerular cells can re-
lease procoagulant substances which lead to fibrin deposition
and damage to the glomerular microcirculation [64). However,
the picture is complex, and much more work is required to
determine the relative contribution of the various cell types.
Therapeutic implications
Because of the multiple components involved in the autoim-
mune process, therapy is likely to involve the use of a number
of different modalities. We will briefly examine some of the
possibilities that arise from considerations of pathogenesis.
Anti-T cell therapy
There are a number of different points at which the autoreac-
tive T cell can be attacked. Thus monoclonal antibodies to the
mouse CD4 molecule, a marker for the T helper/inducer cell
subset, can reverse advanced lupus in a mouse model [65].
Given the fundamental role of class II molecules in the autoim-
mune process, and that the role of the CD4 molecule is probably
to interact with class II molecules, it is not surprising that
anti-class II antibodies can have a similar effect in ameliorating
autoimmune disease, including murine lupus [66]. Unfortu-
nately, attempts to adopt this approach in primates have so far
been limited by severe side effects [66]. Cyclosporin A is
another treatment with powerful effects on T cells and which is
clearly effective in a number of animal models [67, 68] and
possibly also in human nephrotic syndrome resistant to other
modalities of treatment [69]. Prostaglandin E1 also has immu-
nosuppressive properties on T cells [70, 71], and it is possibly
via the production of prostaglandins with attenuated inflamma-
tory action that a diet rich in omega-3 fatty acids (as found in
fish oils) dramatically reduces the severity of murine lupus [72].
Lastly, interleukin 2 (1L2) is a key molecule involved in the
proliferation of T cells. High affinity receptors for 1L2 are only
expressed on activated T cells, and antibodies directed against
these receptors are showing considerable promise in the control
of unwanted immune responses (Strom and Kelley, this issue).
Immunoregulatory therapy
The aim here is to initiate or boost the mechanisms discussed
above that may normally control the immune response.
In an experimental model of anti-TBM nephritis mentioned
earlier (Table 1) treatment with an anti-idiotype against the
major idiotype present on anti-TBM antibodies prevents renal
injury [73]. The treatment is also effective if administered two
weeks into the disease. T cell responses are attenuated, but the
anti-TBM antibody titer is only very slightly lowered. The key
role of T cells is again emphasized, but clearly there is some
form of (presumably) idiotypic connection between the humoral
and cellular systems, Further work is required to define this,
but in any event there are important therapeutic possibilities.
By analogy these are most likely to be realized in human
diseases showing a similarly focused antibody response (Table
1). One possibility is that pooled human gamma globulin may
provide a convenient source of anti-idiotypic antibody. This
material has certainly been successful in the treatment of
immune thrombocytopenic purpura [74] and in down-regulating
anti-factor VIII antibodies [75].
As an extension of this approach, autoreactive T cells in a
number of animal models can be used as "vaccines" to prevent
the development of the associated autoimmune disease, possi-
bly via the development of idiotype-specific cytotoxic cells as
shown in a rat model of autoimmune encephalomyelitis [76].
Once analogous cells are available in man, a similar form of
treatment can be considered. However, given that such cells
would have to be derived anew from each individual, it is
unlikely that this would ever be of more than theoretical
interest, except perhaps in intractable cases of established
autoimmune disease.
Activation of autoantigen-specific suppressor mechanisms is
an attractive therapeutic approach. It has been used to great
effect in animal models, again in anti-TBM nephritis [77]. The
method used is to couple the TBM antigen used to initiate the
autoimmune process to syngeneic lymphocytes, and inject
these back into the animal. Antigen specific suppressor cells are
induced. These are able to attenuate the renal injury even when
induced at up to six weeks after the onset of the autoimmune
process. Because of the use of syngeneic cells, such an ap-
proach is in principle feasible in man, although is presumably
dependent on the use of the correct antigen.
"Clearance" therapy
The concepts outlined in Clearance of immune complexes,
whereby abnormalities of the complement system cause or
exacerbate autoimmunity, have a number of therapeutic conse-
quences. The rational approach to complement deficiency or
depletion is replacement therapy. If the antibodies involved in
immune complex formation are of a class or subclass that does
not fix complement, then their solubilization and clearance will
be inhibited. In this case, immunotherapy would be directed
towards inducing the appropriate class switch.
Concluding remarks
There have been a number of developments in our under-
standing of the mechanisms underlying the establishment of self
tolerance. We now have a clearer picture of the interaction
between antigen and MHC gene products that is the basis for
the initiation of the immune (or autoimmune) response, and the
tools of molecular biology are allowing detailed characteriza-
tion of autoantigens and autoimmune disease-associated MHC
molecules. Progress on the afferent side of autoimmunity is
being matched by the unravelling of the multiple processes that
result in subsequent tissue damage. This understanding can be
expected to have consequences for therapy.
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